Physician profile
Christopher Amen
NPI 1205323961
$23,097.85
in general payments reported to CMS, 2019-2025
33 companies · $10K in 2025
The $10K reported for 2025 was more than what 98% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $660 · 2023: $3,084 · 2024: $8,965 · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Travel and Lodging: $5,986 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,480 · Honoraria: $525 · Consulting Fee: $450.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,996.61 |
| Travel and Lodging | $5,985.88 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,480.00 |
| Honoraria | $525.00 |
| Consulting Fee | $450.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $6,937.23 | 2023-2025 | Intellis Adaptivestim, Inceptiv, Synchromedii |
| Boston Scientific Corporation | $2,712.75 | 2022-2025 | Intracept, General - Pain Management, General - Balloons |
| Abbott Laboratories | $2,531.04 | 2022-2025 | Proclaim |
| Nalu Medical, INC. | $1,928.27 | 2023-2024 | Nalu Neurostimulation System |
| Relievant Medsystems, INC. | $1,467.73 | 2023 | Intracept |
| Abbvie INC. | $1,203.97 | 2023-2025 | Ubrelvy, Qulipta, Botox |
| Protega Pharmaceutials INC | $1,011.06 | 2024-2025 | Roxybond |
| Collegium Pharmaceutical, INC. | $984.00 | 2023-2025 | Belbuca, Xtampza, Nucynta |
| Nevro Corp. | $637.39 | 2023-2024 | Senza |
| Globus Medical, INC. | $362.32 | 2025 | Senza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $305.89 | 2023-2025 | Relistor |
| Painteq LLC | $299.83 | 2023-2024 | Painteq |
| Mml US, INC. | $296.69 | 2024-2025 | Reactiv8 |
| Valinor Pharma, LLC | $292.51 | 2023-2025 | Movantik |
| Scilex Pharmaceuticals INC. | $260.26 | 2024-2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Saluda Medical Americas, INC. | $247.08 | 2025 | Evoke |
| Brixton Biosciences, INC. | $239.32 | 2025 | Neural Ice |
| Vertex Pharmaceuticals Incorporated | $169.24 | 2025 | |
| Forte Bio-Pharma LLC | $168.40 | 2023-2024 | Prolate, Nalocet |
| Stryker Corporation | $155.30 | 2024 | Spinejack |
| Spinal Simplicity, LLC | $146.60 | 2024 | Ha Minuteman G3-R |
| Vertos Medical, INC. | $128.44 | 2024 | Mild Device Kit |
| Bioventus LLC | $126.16 | 2024 | Stimrouter Implantable Kit |
| Spr Therapeutics, INC | $99.64 | 2022-2025 | Sprint Pns System |
| Lundbeck LLC | $92.40 | 2024-2025 | Vyepti |
| Indivior INC. | $56.70 | 2024-2025 | Sublocade |
| Curonix LLC | $49.26 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Pfizer INC. | $48.56 | 2023 | |
| Azurity Pharmaceuticals, INC. | $35.88 | 2025 | Horizant |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.36 | 2022 | |
| Axsome Therapeutics, INC. | $26.53 | 2025 | Symbravo |
| Ipsen Biopharmaceuticals, INC | $24.14 | 2025 | Dysport |
| Depuy Synthes Sales INC. | $19.90 | 2023 | Orthovisc, Monovisc, Peak |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Amen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.